Author: Dino Mustafić

December 8, 2020 Off

Actinium reports complete response in the Actimab-A venetoclax combination trial

By Dino Mustafić

Actinium Pharmaceuticals has reported 67% overall response rate in first cohort in Actimab-A Venetoclax combination trial in relapsed and refractory AML at ASH, which includes one complete response in patient with TP53 mutation and one partial response reported in patients with poor risk adverse cytogenetics with subtherapeutic dose of Actimab-A indicative of mechanistic synergy with venetoclax.

December 8, 2020 Off

Osteolabs nets €1.6 in second financing round

By Dino Mustafić

Osteolab has completed a second financing round in the amount of approximately €1.6 million. The funds were provided by Seed and Start-Up Fonds II of MBG (Mittelständische Beteiligungsgesellschaft) Kiel, Labor Dr. Krause & Kollegen MVZ GmbH, Kiel, and SVM Verwaltungsgesellschaft mbH, Hamburg, as new shareholders.

December 2, 2020 Off

BD invests $1.2 billion over 4 years

By Dino Mustafić

BD (Becton, Dickinson and Company) plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.